How much echo left ventricular hypertrophy would be missed in diabetics by applying the Losartan Intervention For Endpoint Reduction electrocardiogram criteria to select patients for angiotensin receptor blockade?

Adelle Dawson, Bushra S Rana, Stuart D Pringle, Louise A Donnelly, Andrew D Morris, Allan D Struthers

    Research output: Contribution to journalArticle

    7 Citations (Scopus)


    The Losartan Intervention For Endpoint Reduction (LIFE) study demonstrated a clear mortality benefit in treating hypertensive patients with electrocardiogram (ECG) evidence of left ventricular hypertrophy (LVH) with losartan rather than atenolol. Previous studies have also shown that identifying and treating echo LVH is associated with prognostic benefits in hypertensive subjects, and is independent of the presence of ECG LVH. We sought to determine how many cases of echo LVH would be missed by applying the ECG criteria for LVH used in the LIFE study.
    Original languageEnglish
    Pages (from-to)1403-8
    Number of pages6
    JournalJournal of Hypertension
    Issue number7
    Publication statusPublished - 2004


    Cite this